唯择®(阿贝西利片)
本页包括过去3年在同行评审期刊上发表的礼来发起的临床试验。
以下列表仅限于与已批准使用的产品相关的出版物,
可能是非适应症的。(请参见产品完整处方信息链接)
如果您对下面未列出的礼来研究有任何疑问,或希望获得本页期刊出版物的电子版,
请联系下面的礼来服务部以获得进一步的帮助。
阿贝西利联合帕博利珠单抗治疗 HR+、HER2- 转移性乳腺癌:1b 期研究
Abemaciclib in combination with pembrolizumab for HR+, HER2- metastatic breast cancer: Phase 1b study
发表日期:2022-11-05
阿贝西利联合内分泌治疗用于激素受体阳性、HER2 阴性转移性乳腺癌:1b 期研究
Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study
发表日期:2022-02-10
新型抗PD-L1抗体单药治疗或联合靶向治疗在晚期实体瘤中的安全性和临床活性:PACT Ia/Ib期试验
Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial
发表日期:2021-03-01
一项在晚期和/或转移性癌症的中国患者中评价阿贝西利的随机I期研究
A Randomized Phase I Study of Abemaciclib in Chinese Patients with Advanced and/or Metastatic Cancers
发表日期:2021-01-25
在5个欧洲国家接受HR +/HER2-晚期乳腺癌初始内分泌治疗的女性的真实世界患者报告结局
Real-world patient-reported outcomes of women receiving initial endocrine-based therapy for HR+/HER2− advanced breast cancer in five European countries
发表日期:2020-09-07
阿贝西利对癌症患者CYP1A2、CYP2 C9、CYP2D6和CYP3A4底物的药代动力学无具有临床意义的影响
Abemaciclib Does Not Have a Clinically Meaningful Effect on Pharmacokinetics of CYP1A2, CYP2C9, CYP2D6, and CYP3A4 Substrates in Patients with Cancer
发表日期:2020-08-17
一项开放标签、随机 2 期试验,评估食物对晚期乳腺癌患者对阿贝西利耐受性的影响
An open label, randomized phase 2 trial assessing the impact of food on the tolerability of abemaciclib in patients with advanced breast cancer
发表日期:2022-08-01
nextMONARCH 2 期随机临床试验:阿贝西利单药治疗或与他莫昔芬联合治疗内分泌难治性 HR+、HER2- 转移性乳腺癌患者的总生存分析
nextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine‑refractory HR+, HER2– metastatic breast cancer
发表日期:2022-07-12
阿贝西利联合内分泌治疗在激素受体阳性/人表皮生长因子受体2阴性的晚期乳腺癌老年患者中的安全性和疗效:MONARCH 2和3试验的年龄特异性亚组分析
Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials
发表日期:2021-01-03
nextMONARCH:阿贝西利单药治疗或联合他莫昔芬治疗转移性乳腺癌
nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast Cancer
发表日期:2020-09-30
既往多线治疗的难治性HR +、HER2-转移性乳腺癌患者接受单药化疗的真实世界生存结局-与MONARCH 1的比较
Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2−metastatic breast cancer receiving single-agent chemotherapy—a comparison with MONARCH 1
发表日期:2020-08-12
一项在激素受体阳性乳腺癌继发脑转移患者中进行的阿贝西利 Ⅱ期研究
A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor–Positive Breast Cancer
发表日期:2020-07-21
阿贝西利在复发性或难治性套细胞淋巴瘤患者中的临床活性-一项Ⅱ期研究
Clinical activity of abemaciclib in patients with relapsed or refractory mantle cell lymphoma - a phase II study
发表日期:2020-05-07
阿贝西利 +曲妥珠单抗±氟维司群 vs曲妥珠单抗+标准化疗治疗激素受体阳性、her2阳性晚期乳腺癌(monarcHER):一项随机、开放标签的2期试验
Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial
发表日期:2020-04-27
辅助阿贝西利联合内分泌治疗 (ET):monarchE 队列 1 的疗效结果
Adjuvant Abemaciclib Combined with Endocrine Therapy (ET): Efficacy Results in monarchE Cohort 1
发表日期:2022-11-07
基于人群的 Oncotype Dx 乳腺癌复发评分® 结果与 Ki-67 IHC MIB-1 pharmDx 在 HR+、HER2-、淋巴结阳性早期乳腺癌中的相关性估计
Population-based estimate for the correlation of the Oncotype Dx Breast Recurrence Score® result and Ki-67 IHC MIB-1 pharmDx in HR+, HER2-, node-positive early breast cancer
发表日期:2022-11-01
阿贝西利联合氟维司群治疗 HR+、HER2- 晚期乳腺癌的东亚女性数据: MONARCH 2 的总生存
Abemaciclib plus fulvestrant in East Asian women with HR+, HER2- advanced breast cancer: Overall Survival from MONARCH 2
发表日期:2022-09-28
美国 FDA 批准的用于评估 Ki-67 在高危早期乳腺癌中的试剂的两种仪器比较
Two Instrument Comparison of Reagents From a US FDA-Approved Assay for the Assessment of Ki-67 in High-Risk Early Breast Cancer
发表日期:2022-09-01
根据高危临床和病理特征定义的早期乳腺癌中的乳腺癌特异性死亡率
Breast cancer-specific mortality in early breast cancer as defined by high-risk clinical and pathologic characteristics
发表日期:2022-02-25
CDK4/6抑制剂Abemaciclib治疗乳腺癌临床进展的叙述性综述
A narrative review of the clinical development of CDK4/6 inhibitor Abemaciclib in breast cancer
发表日期:2022-01-31
在 monarchE 3 期临床研究中用于评估高危早期乳腺癌患者的标准化研究性 Ki-67 免疫组织化学分析确定了单独接受内分泌治疗时疾病复发风险更高的人群
A Standardized Investigational Ki-67 Immunohistochemistry Assay Used to Assess High-Risk Early Breast Cancer Patients in the monarchE Phase 3 Clinical Study Identifies a Population With Greater Risk of Disease Recurrence When Treated With Endocrine Therapy Alone
发表日期:2022-01-25
激素受体阳性、人表皮生长因子受体2阴性晚期乳腺癌患者中阿贝西利相关不良事件的管理:MONARCH 2和MONARCH 3的安全性分析
Management of Abemaciclib‐Associated Adverse Events in Patients with Hormone Receptor‐Positive, Human Epidermal Growth Factor Receptor 2‐Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3
发表日期:2021-09-21
MONARCH 2:接受阿贝西利加氟维司群作为 HR+、HER2-晚期乳腺癌一线和二线治疗的患者的亚组分析
MONARCH 2: subgroup analysis of patients receiving abemaciclib plus fulvestrant as first-line and second-line therapy for HR+, HER2- advanced breast cancer
发表日期:2021-09-07
阿贝西利联合氟维司群治疗激素受体阳性、HER2阴性的绝经前和围绝经期女性晚期乳腺癌:MONARCH 2试验亚组分析
Abemaciclib plus fulvestrant in hormone receptor positive, HER2-negative advanced breast cancer in premenopausal and perimenopausal women: a subgroup analysis from MONARCH 2 trial
发表日期:2021-08-31
阿贝西利作为晚期乳腺癌的初始治疗:MONARCH 3亚组预后的最新结果
Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups
发表日期:2021-06-15
MONARCH 2的日本亚组分析:阿贝西利 + 氟维司群治疗内分泌治疗后进展的激素受体阳性、人表皮生长因子受体2阴性乳腺癌的Ⅲ期研究
Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy
发表日期:2021-04-01
阿贝西利联合内分泌治疗在激素受体阳性/人表皮生长因子受体2阴性的晚期乳腺癌老年患者中的安全性和疗效:MONARCH 2和3试验的年龄特异性亚组分析
Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials
发表日期:2021-01-03
社区肿瘤环境中HR +/HER2-转移性乳腺癌女性患者预后因素指数的发展
Development of a Prognostic Factor Index Among Women With HR+/HER2− Metastatic Breast Cancer in a Community Oncology Setting
发表日期:2021-01-01
一项在既往铂类药物治疗失败的携带可检测KRAS突变的IV期非小细胞肺癌患者中比较阿贝西利与厄洛替尼的随机Ⅲ期研究:JUNIPER
A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable KRAS Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER
发表日期:2020-10-26
MONARCH plus:阿贝西利 + 内分泌治疗用于HR +/HER2-晚期乳腺癌女性患者:多国随机Ⅲ期研究
MONARCH plus: abemaciclib plus endocrine therapy in women with HR+/HER2– advanced breast cancer: the multinational randomized phase III study
发表日期:2020-10-22
阿贝西利联合内分泌治疗辅助治疗HR +、HER2-、淋巴结阳性、高危、早期乳腺癌(monarchE)
Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
发表日期:2020-09-20
MONARCH 3中的健康相关生命质量:阿贝西利 + 芳香化酶抑制剂作为HR +、HER2-晚期乳腺癌的初始治疗
Health‐Related Quality of Life in MONARCH 3: Abemaciclib plus an Aromatase Inhibitor as Initial Therapy in HR+, HER2− Advanced Breast Cancer
发表日期:2020-06-14